<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Oxymetholone (United States: Not available): Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Oxymetholone (United States: Not available): Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Oxymetholone (United States: Not available): Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="11858" href="/d/html/11858.html" rel="external">see "Oxymetholone (United States: Not available): Patient drug information"</a> and <a class="drug drug_pediatric" data-topicid="97035" href="/d/html/97035.html" rel="external">see "Oxymetholone (United States: Not available): Pediatric drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="block black-box-warn drugH1Div" id="F5709188"><span class="drugH1">ALERT: US Boxed Warning</span>
<div class="collapsible">
<span class="collapsible-title">Peliosis hepatis:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Peliosis hepatis, a condition in which liver and, sometimes, splenic tissue is replaced with blood-filled cysts, has occurred in patients receiving androgenic anabolic steroids. These cysts are sometimes present with minimal hepatic dysfunction and have been associated with liver failure. Often, they are not recognized until life-threatening liver failure or intra-abdominal hemorrhage develops. Withdrawal of drug usually results in complete disappearance of lesions.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Liver cell tumors:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Most often these tumors are benign and androgen-dependent, but fatal malignant tumors have occurred. Withdrawal of drug often results in regression or cessation of tumor progression. However, hepatic tumors associated with androgens or anabolic steroids are much more vascular than other hepatic tumors and may be silent until life-threatening, intra-abdominal hemorrhage develops.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Blood lipid changes:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Blood lipid changes associated with increased risk of atherosclerosis are seen in patients treated with androgens and anabolic steroids. These changes include decreased high-density lipoprotein (HDL) and, sometimes, increased low-density lipoprotein (LDL). The changes may be very marked and could have a serious impact on the risk of atherosclerosis and coronary artery disease.</p></div>
</div>
</div>
<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F205251"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Anadrol-50 [DSC]</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F205273"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Anabolic Steroid</li></ul></div>
<div class="block doa drugH1Div" id="F205253"><span class="drugH1">Dosing: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Anadrol-50 has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="1b09a5f2-c380-4caf-8985-905aef967fb6">Erythropoietic effects</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erythropoietic effects:</b>
<b>Oral:</b> 1 to 5 mg/kg/day once daily; usual effective dose: 1 to 2 mg/kg/day; give for a minimum trial of 3 to 6 months because response may be delayed.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="858f019b-e710-46a8-92c9-43880949c068">Fanconi anemia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Fanconi anemia (alternative agent) (off-label use):</b> Limited data available: <b>Oral:</b> Initial: 2 mg/kg/day (median dose reported); most patients had a documented dose reduction although exact doses were not provided; <i>duration of therapy:</i> 4.1 years (median for responders); 1.3 years (median for nonresponders) (Paustian 2016) <b>or</b> Initial: ~2 mg/kg/day; if response observed, slowly taper in 10% to 20% decrements every 3 to 4 months to achieve the lowest effective dose; doses up to 5 mg/kg/day may be required; discontinue if no response in blood counts (in the absence of other causes such as infection) after 3 to 4 months (FARF [Sroka 2020]).</p></div>
</div>
</div>
<div class="block dora drugH1Div" id="F50990231"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">No dosage adjustment provided in manufacturer’s labeling. Use with caution due to risk of edema in patients with renal impairment.</p></div>
<div class="block doha drugH1Div" id="F50987541"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Mild to moderate impairment: There are no dosage adjustments provided in the manufacturer’s labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Severe impairment: Use is contraindicated.</p></div>
<div class="block doe drugH1Div" id="F205254"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:0em;display:inline">Refer to adult dosing.</p></div>
<div class="block dop drugH1Div" id="F205264"><span class="drugH1">Dosing: Pediatric</span><p>(For additional information <a class="drug drug_pediatric" data-topicid="97035" href="/d/html/97035.html" rel="external">see "Oxymetholone (United States: Not available): Pediatric drug information"</a>)</p>
<p style="text-indent:0em;display:inline">
<b>Note:</b> Anadrol-50 has been discontinued in the United States for &gt;1 year.</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="74742cfb-4e1f-4411-998e-0c175e57daec">Anemia, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Anemia, treatment (erythropoietic effect [eg, Fanconi anemia, bone marrow failure syndromes]):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Children and Adolescents: Oral: Initial: ~2 mg/kg/day, rounded to nearest 12.5 mg (ie, <sup>1</sup>/<sub>4</sub> of the 50 mg tablet); usual range: 1 to 5 mg/kg/day once daily; some have suggested higher dosing initially (2 to 5 mg/kg/day) and after response, a slow taper (eg, decrease dose by 10% to 20% every 3 to 4 months) to lowest effective dose with minimal side effects; typically, therapeutic response of stabilization or improvement in hemoglobin or platelet counts is observed within 3 to 6 months (Camitta 1979; FARF 2014). <b>Note:</b> The National Kidney Foundation recommends against the use of androgens as an adjuvant to erythropoiesis-stimulating agent treatment in anemic patients with chronic kidney disease (KDIGO 2012; KDOQI 2006). Although an FDA-approved indication, oxymetholone use in the treatment of aplastic anemia has been replaced by newer therapies with improved outcomes (eg, hematopoietic stem cell transplantation, immunosuppressive therapy) (BSH [Samarasinghe 2017]; NAPAAC [Rogers 2019]).</p></div>
</div>
</div>
<div class="block dorp drugH1Div" id="F51151400"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Children and Adolescents: There are no dosage adjustments provided in manufacturer's labeling. Use with caution due to risk of edema in patients with renal impairment; use is contraindicated in patients with nephrosis or patients in the nephrotic phase of nephritis.</p></div>
<div class="block dohp drugH1Div" id="F51151401"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Children and Adolescents:</p>
<p style="text-indent:-2em;margin-left:4em;">Mild to moderate hepatic impairment: There are no dosage adjustments provided in manufacturer's labeling. Use with caution in patients with liver dysfunction because of its hepatotoxic potential.</p>
<p style="text-indent:-2em;margin-left:4em;">Severe hepatic impairment: Use is contraindicated</p></div>
<div class="block adr drugH1Div" id="F205229"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:0em;">Frequency not defined:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Coronary artery disease, peripheral edema</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Chills, deepening of the voice (females), excitement, insomnia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acne vulgaris, androgenetic alopecia (postpubertal males, females), hyperpigmentation</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Amenorrhea, change in libido (decreased/increased), decreased glucose tolerance, decreased HDL cholesterol, gynecomastia, hirsutism (women), hypercalcemia, hyperchloremia, hyperkalemia, hypernatremia, hyperphosphatemia, increased LDL cholesterol, menstrual disease</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Diarrhea, nausea, vomiting</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Benign prostatic hypertrophy (elderly males), clitoromegaly, decreased ejaculate volume, epididymitis, erectile dysfunction (increased erections; prepubertal males), impotence, irritable bladder, oligospermia, phallic enlargement, priapism, testicular atrophy, testicular disease, virilization (females)</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Clotting factors suppression (II, V, VII, X), hemorrhage, increased INR, iron deficiency anemia, leukemia, malignant neoplasm of prostate, prolonged prothrombin time</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis, cholestatic jaundice, hepatic failure, hepatic necrosis, hepatocellular neoplasm (including carcinoma), increased serum alkaline phosphatase, increased serum bilirubin, increased serum transaminases, peliosis hepatitis</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Increased creatine phosphokinase, premature epiphyseal closure (children)</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Increased serum creatinine</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Hoarseness (females)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Hepatotoxicity (idiosyncratic; Chalasani 2014)</p></div>
<div class="block coi drugH1Div" id="F205243"><span class="drugH1">Contraindications</span>
<p style="text-indent:0em;display:inline">Hypersensitivity to oxymetholone or any component of the formulation; breast cancer in men; breast cancer in women with hypercalcemia; prostate cancer; severe hepatic dysfunction; nephrosis or nephrotic phase of nephritis; pregnancy or use in women who may become pregnant</p></div>
<div class="block war drugH1Div" id="F205226"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Blood lipid changes: <b>[US Boxed Warning]: Anabolic steroids may cause changes in blood lipids (decreased high density lipoproteins and sometimes increased low density lipoproteins), increasing the risk of arteriosclerosis and coronary artery disease.</b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clotting factor alterations: Anabolic steroids may suppress factors II, V, VII, and X; prothrombin time may be increased.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic effects: <b>[US Boxed Warning]: Androgenic anabolic steroid treatment may cause peliosis hepatis, which occurs when splenic or hepatic tissue is replaced by cysts (blood-filled); may only cause minimal hepatic dysfunction although has been associated with hepatic failure. Androgenic liver cell tumors, which may be benign, although malignant tumors have also been reported; generally regress when anabolic steroid treatment is withdrawn. Both conditions (peliosis and tumors) may not be apparent until liver failure or intra-abdominal hemorrhage develops.</b> Androgen use (low doses) has also been associated with cholestatic hepatitis and jaundice; may be associated with hepatomegaly and right upper-quadrant pain; jaundice is typically reversible upon discontinuation (continuing treatment has been associated with coma and death). Monitor liver function periodically.</p>
<p style="text-indent:-2em;margin-left:4em;">• Prostate conditions: Androgenic anabolic steroid use may cause prostatic hypertrophy or prostate cancer in elderly men.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Breast cancer: May cause hypercalcemia in women with breast cancer by stimulating osteolysis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Diabetes: Use with caution in patients with diabetes mellitus; insulin or oral hypoglycemic needs may be altered; monitor carefully.</p>
<p style="text-indent:-2em;margin-left:4em;">• Edematous conditions: Use with caution in patients with conditions influenced by edema (eg, cardiovascular disease, migraine, seizure disorder, renal impairment); may cause fluid retention.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Pediatric: May accelerate bone maturation without producing compensatory gain in linear growth in children; effect may continue for 6 months after treatment discontinuation; in prepubertal children perform radiographic examination of the hand and wrist every 6 months to determine the rate of bone maturation and to assess the effect of treatment on the epiphyseal centers.</p>
<p style="text-indent:-2em;margin-left:4em;">• Women: Discontinue with evidence of mild virilization in women.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Oxymetholone should not replace other anemia treatment supportive measures such as transfusion, correction of iron, folic acid, vitamin B<sub>12</sub> or pyridoxine deficiency, antibacterial therapy, and the appropriate use of corticosteroids.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F52878574"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">In children, androgens are not recommended for management of anemia associated with chronic kidney disease and should not be used (KDIGO 2006).</p>
<p style="text-indent:0em;margin-top:2em;">Oxymetholone may cause virilization in females; monitor for signs of virilization (eg, deepening of voice, hirsutism, acne, and clitoromegaly); discontinue use if evidence of mild virilization; discontinuation may prevent irreversible virilization.</p></div>
<div class="block prod-avail drugH1Div" id="F56709727"><span class="drugH1">Product Availability</span>
<p style="text-indent:0em;display:inline">Anadrol-50 has been discontinued in the United States for &gt;1 year.</p></div>
<div class="block foc drugH1Div" id="F205239"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Anadrol-50: 50 mg [DSC] [scored]</p></div>
<div class="block geq drugH1Div" id="F205222"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">No</p></div>
<div class="block fee drugH1Div" id="F16323584"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Anadrol-50 Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">50 mg (per each): $50.96</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block csi drugH1Div" id="F205275"><span class="drugH1">Controlled Substance</span>
<p style="text-indent:0em;display:inline">C-III</p></div>
<div class="block admp drugH1Div" id="F52617909"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:0em;display:inline">Oral: May administer without regard to meals; tablets may be cut to achieve partial doses (FARF 2014).</p></div>
<div class="block use drugH1Div" id="F205241"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Anemia:</b> Treatment of anemias caused by deficient red cell production. <b>Note:</b> Androgen therapy (eg, oxymetholone) is generally not appropriate for the treatment of anemias except in certain rare situations (eg, Fanconi anemia).</p></div>
<div class="block off-label drugH1Div" id="F50215357"><span class="drugH1">Use: Off-Label: Adult</span><p>Fanconi anemia (alternative agent)</p></div>
<div class="block mst drugH1Div" id="F205279"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Oxymetholone may be confused with oxymetazoline, oxyMORphone</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs that have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F13299806"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">None known.</p></div>
<div class="block dri drugH1Div" id="F205231"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Agents with Blood Glucose Lowering Effects: Androgens may enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Androgens may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">C1 inhibitors: Androgens may enhance the thrombogenic effect of C1 inhibitors. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Corticosteroids (Systemic): May enhance the fluid-retaining effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Androgens may enhance the hepatotoxic effect of CycloSPORINE (Systemic). Androgens may increase the serum concentration of CycloSPORINE (Systemic).  Management: Consider avoiding concomitant use of androgens and cyclosporine. If concomitant use is unavoidable, monitor serum cyclosporine concentrations and for signs and symptoms of hepatotoxicity. Cyclosporine dose reductions may be required.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypertension-Associated Agents: May enhance the hypertensive effect of Androgens.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Androgens may enhance the anticoagulant effect of Vitamin K Antagonists.  Management: Monitor for increased effects of vitamin K antagonists if an androgen is initiated/dose increased, or decreased effects if androgen is discontinued/dose decreased. Significant reductions in vitamin K antagonist dose are likely required.<i> Risk D: Consider therapy modification</i></p></div>
<div class="block rep_considerations drugH1Div" id="F49308604"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in women who may become pregnant.</p>
<p style="text-indent:0em;margin-top:2em;">Oligospermia or amenorrhea may occur resulting in an impairment of fertility.</p></div>
<div class="block pri drugH1Div" id="F205244"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Use is contraindicated in women who are pregnant.</p></div>
<div class="block brc drugH1Div" id="F20548707"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if oxymetholone is excreted in breast milk. Breastfeeding is not recommended by the manufacturer.</p></div>
<div class="block mop drugH1Div" id="F205236"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:0em;display:inline">Periodic liver function tests, lipid profile, hemoglobin and hematocrit; iron studies; serum glucose (may be decreased by testosterone, monitor patients with diabetes); radiologic examination of bones every 6 months (when using in prepubertal children); monitor urine and serum calcium and signs of virilization in women treated for breast cancer</p></div>
<div class="block pha drugH1Div" id="F205225"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Enhances production of erythropoietin in patients with anemias which are due to bone marrow failure; stimulates erythropoiesis in anemias due to deficient red cell production</p></div>
<div class="block phk drugH1Div" id="F46148568"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:0em;margin-left:0em;display:inline">Onset of action: Response is not often immediate; a minimum trial of 3 to 6 months is recommended</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F205245"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adroyd</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Hemogenin</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Anapolon</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Anasteron</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Anapolon</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Adroyd | Anadrol</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Anadrol | Celltrion Oxymetholone</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Anapolon</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Anapolon</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Han seo oxymetholone | Oxylone</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Anapolon</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Oxitoland</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Anasteron</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Androgan | Androlic | Oxymedon</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Anapolon</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference">
                  Anadrol-50 (oxymetholone) [prescribing information]. Marietta, GA: Alavan Pharmaceuticals; December 2006.</div>
</li>
<li>
<div class="reference">
                  Camitta BM, Thomas ED, Nathan DG, et al. A prospective study of androgens and bone marrow transplantation for treatment of severe aplastic anemia. <i>Blood</i>. 1979;53(3):504-514.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-966.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetholone-united-states-not-available-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference">
                  Fanconi Anemia Research Fund, Inc. <i>Fanconi Anemia: Guidelines for Diagnosis and Management</i>. 4th ed. 2014.</div>
</li>
<li>
<div class="reference">
                  KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. <i>Kidney International Supplements</i>. 2012;2:279.</div>
</li>
<li>
<div class="reference">
                  KDOQI Clinical Practice Guideline and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease. Published 2006. Available at: http://www2.kidney.org/professionals/KDOQI/guidelines_anemia/.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26900943">
<a name="26900943"></a>Paustian L, Chao MM, Hanenberg H, et al. Androgen therapy in fanconi anemia: a retrospective analysis of 30 years in Germany. <i>Pediatr Hematol Oncol</i>. 2016;33(1):5-12.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetholone-united-states-not-available-drug-information/abstract-text/26900943/pubmed" id="26900943" target="_blank">26900943</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30948484">
<a name="30948484"></a>Rogers ZR, Nakano TA, Olson TS, et al. Immunosuppressive therapy for pediatric aplastic anemia: a North American Pediatric Aplastic Anemia Consortium study. <i>Haematologica</i>. 2019;104(10):1974-1983.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetholone-united-states-not-available-drug-information/abstract-text/30948484/pubmed" id="30948484" target="_blank">30948484</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29285764">
<a name="29285764"></a>Samarasinghe S, Veys P, Vora A, Wynn R. Paediatric amendment to adult BSH guidelines for aplastic anaemia. <i>Br J Haematol</i>. 2018;180(2):201-205.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/oxymetholone-united-states-not-available-drug-information/abstract-text/29285764/pubmed" id="29285764" target="_blank">29285764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Sroka.2020">
<a name="Sroka.2020"></a>Sroka I, Frohnmayer L, Van Ravenhorst S, et al, eds. Fanconi anemia clinical care guidelines. 5th edition. Fanconi Anemia Research Fund; 2020. https://www.fanconi.org/images/uploads/other/Fanconi_Anemia_Clinical_Care_Guidelines_5thEdition_web.pdf. Accessed February 18, 2022.</div>
</li></ol></div><div id="topicVersionRevision">Topic 9732 Version 129.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
